Title |
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014
|
---|---|
Published in |
Journal of Translational Medicine, October 2014
|
DOI | 10.1186/s12967-014-0291-1 |
Pubmed ID | |
Authors |
Paolo A Ascierto, Raffaele Addeo, Giacomo Cartenì, Bruno Daniele, Michele De Laurentis, Giovanni Pietro Ianniello, Alessandro Morabito, Giovannella Palmieri, Stefano Pepe, Francesco Perrone, Sandro Pignata, Vincenzo Montesarchio |
Abstract |
The therapeutic approach to advanced or metastatic solid tumors, either with chemotherapy or targeted therapies, is mainly palliative. Resistance to chemotherapy occurs very frequently and is one of the most important reasons for disease progression. Immunotherapy has the potential to mount an ongoing, dynamic immune response that can kill tumor cells for an extended time after the conventional therapy has been administered. Such a long-lasting response is potentially able to completely eradicate tumor cells, rather than producing only a temporary killing of cells. The most promising immune-based treatments are monoclonal antibodies that act as checkpoint inhibitors (e.g. ipilimumab and nivolumab), adoptive cell therapy (e.g. T-cells expressing chimeric antigen receptors) and vaccines (e.g. sipuleucel-T). Ipilimumab is currently approved for the treatment of metastatic melanoma and sipuleucel-T is approved for advanced prostate cancer. There is great interest in immunotherapy in other solid tumors, potentially used alone or in a multimodal fashion with chemotherapy and/or biological drugs. In this paper, we review recent advances in immuno-oncology in solid malignancies (except melanoma) as were discussed at the inaugural meeting of the Campania Society of Oncology Immunotherapy (SCITO). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 4 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Ecuador | 1 | 1% |
Korea, Republic of | 1 | 1% |
Unknown | 77 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 16 | 20% |
Researcher | 12 | 15% |
Student > Ph. D. Student | 10 | 13% |
Other | 9 | 11% |
Student > Master | 6 | 8% |
Other | 9 | 11% |
Unknown | 18 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 36% |
Biochemistry, Genetics and Molecular Biology | 7 | 9% |
Agricultural and Biological Sciences | 6 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
Nursing and Health Professions | 4 | 5% |
Other | 8 | 10% |
Unknown | 21 | 26% |